S&P 500   4,970.64 (-0.81%)
DOW   37,853.71 (+0.21%)
QQQ   416.58 (-1.61%)
AAPL   164.51 (-1.51%)
MSFT   399.91 (-1.08%)
META   483.86 (-3.58%)
GOOGL   153.76 (-1.44%)
AMZN   175.28 (-2.20%)
TSLA   149.19 (-0.49%)
NVDA   807.88 (-4.59%)
AMD   148.19 (-4.44%)
NIO   3.83 (-4.25%)
BABA   68.60 (-0.41%)
T   16.35 (+0.12%)
F   12.10 (+0.33%)
MU   107.31 (-4.13%)
GE   149.30 (-2.38%)
CGC   8.04 (+2.68%)
DIS   111.60 (-0.74%)
AMC   3.22 (+10.27%)
PFE   25.84 (+1.77%)
PYPL   61.92 (-0.29%)
XOM   120.03 (+1.27%)
S&P 500   4,970.64 (-0.81%)
DOW   37,853.71 (+0.21%)
QQQ   416.58 (-1.61%)
AAPL   164.51 (-1.51%)
MSFT   399.91 (-1.08%)
META   483.86 (-3.58%)
GOOGL   153.76 (-1.44%)
AMZN   175.28 (-2.20%)
TSLA   149.19 (-0.49%)
NVDA   807.88 (-4.59%)
AMD   148.19 (-4.44%)
NIO   3.83 (-4.25%)
BABA   68.60 (-0.41%)
T   16.35 (+0.12%)
F   12.10 (+0.33%)
MU   107.31 (-4.13%)
GE   149.30 (-2.38%)
CGC   8.04 (+2.68%)
DIS   111.60 (-0.74%)
AMC   3.22 (+10.27%)
PFE   25.84 (+1.77%)
PYPL   61.92 (-0.29%)
XOM   120.03 (+1.27%)
S&P 500   4,970.64 (-0.81%)
DOW   37,853.71 (+0.21%)
QQQ   416.58 (-1.61%)
AAPL   164.51 (-1.51%)
MSFT   399.91 (-1.08%)
META   483.86 (-3.58%)
GOOGL   153.76 (-1.44%)
AMZN   175.28 (-2.20%)
TSLA   149.19 (-0.49%)
NVDA   807.88 (-4.59%)
AMD   148.19 (-4.44%)
NIO   3.83 (-4.25%)
BABA   68.60 (-0.41%)
T   16.35 (+0.12%)
F   12.10 (+0.33%)
MU   107.31 (-4.13%)
GE   149.30 (-2.38%)
CGC   8.04 (+2.68%)
DIS   111.60 (-0.74%)
AMC   3.22 (+10.27%)
PFE   25.84 (+1.77%)
PYPL   61.92 (-0.29%)
XOM   120.03 (+1.27%)
S&P 500   4,970.64 (-0.81%)
DOW   37,853.71 (+0.21%)
QQQ   416.58 (-1.61%)
AAPL   164.51 (-1.51%)
MSFT   399.91 (-1.08%)
META   483.86 (-3.58%)
GOOGL   153.76 (-1.44%)
AMZN   175.28 (-2.20%)
TSLA   149.19 (-0.49%)
NVDA   807.88 (-4.59%)
AMD   148.19 (-4.44%)
NIO   3.83 (-4.25%)
BABA   68.60 (-0.41%)
T   16.35 (+0.12%)
F   12.10 (+0.33%)
MU   107.31 (-4.13%)
GE   149.30 (-2.38%)
CGC   8.04 (+2.68%)
DIS   111.60 (-0.74%)
AMC   3.22 (+10.27%)
PFE   25.84 (+1.77%)
PYPL   61.92 (-0.29%)
XOM   120.03 (+1.27%)
Free Trial
OTCMKTS:NRIFF

Nuvo Pharmaceuticals (NRIFF) Stock Price, News & Analysis

→ Healthcare Takes A Big Step Forward With The Help Of AI (From The Bull Report) (Ad)
Free NRIFF Stock Alerts
Compare
Today's Range
N/A
50-Day Range
$0.75
▼
$0.75
52-Week Range
N/A
Volume
3,000 shs
Average Volume
7,337 shs
Market Capitalization
$8.52 million
P/E Ratio
18.69
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis

About Nuvo Pharmaceuticals

Nuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. It operates through the following segments: Commercial Business, Production and Service Business and Licensing and Royalty Business. The Commercial Business segment includes Blexten, Cambia, the canadian business for Resultz and Suvexx, and mature assets. The Production and Service Business segment supplies Pennsaid to Horizon for the U.S. market and is engaged in ongoing partnering efforts for Pennsaid. The Licensing and Royalty Business segment engages in the selling of Vimovo. Nuvo Pharmaceuticals was founded on August 22, 1983 and is headquartered in Mississauga, Canada.

NRIFF Stock News Headlines

February 14, 2024 | forbes.com
4 Best Home Oxygen Concentrators Of 2024
July 29, 2021 | benzinga.com
Miravo HealthcareTM Ireland Enters into Suvexx® License and Supply Agreement with SK Chemicals Co., Ltd. for South Korea
See More Headlines
Receive NRIFF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nuvo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:NRIFF
CUSIP
N/A
CIK
N/A
Web
www.nuvopharmaceuticals.com
Phone
(905) 673-6980
Fax
N/A
Employees
99
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
$0.04
Trailing P/E Ratio
18.69
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$2.53 million
Net Margins
-2.81%
Pretax Margin
N/A
Return on Equity
8.02%
Return on Assets
1.11%

Debt

Debt-to-Equity Ratio
5.27
Current Ratio
2.67
Quick Ratio
2.11

Sales & Book Value

Annual Sales
$52.41 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
0.82
Book Value
$1.59 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
11,400,000
Free Float
N/A
Market Cap
$8.52 million
Optionable
Not Optionable
Beta
1.57
The 10 Best AI Stocks to Own in 2024 Cover
The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Jesse Ledger
    President & Chief Executive Officer
  • Kelly Demerino
    Chief Financial Officer
  • Bernard Chiasson
    Chief Scientific Officer
  • Wade Hull
    Vice President-Research & Development
  • Katina K. Loucaides
    Secretary, Vice President & General Counsel

Key Competitors

View All Competitors

NRIFF Stock Analysis - Frequently Asked Questions

How do I buy shares of Nuvo Pharmaceuticals?

Shares of NRIFF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:NRIFF) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
Biden’s $374B Giveaway Into This Sector
DTI
The #1 Crypto for 2024
InvestorPlace
He Is Giving Away Bitcoin
Crypto Swap Profits
Urgent alert: open this for a huge profit potential
Timothy Sykes
How Biden has already won 2024
Porter & Company
My biggest AI fear
Paradigm Press
Options trading has suddenly become more reliable.
Eagle Publishing